FindTrial
Sign In

Clinical research of autologous mutation peptides for the treatment of Hepatocellular Carcinoma

Clinical research of autologous mutation peptides for the treatment of Hepatocellular Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-16010127
Enrollment
Unknown
Registered
2016-12-11
Start date
2017-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

Control group:Routine treatment for hepatocellular carcinoma+ subcutaneous injection of normal saline on both arms, once a week, for 12 weeks
Study group:Routine treatment for hepatocellular carcinoma+ subcutaneous injection of autologous mutation peptides on both arms, once a week, for 12 weeks

Sponsors

Tianjin Beichen Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Any clinical stage Hepatocellular Carcinoma patients with an estimated life expectancy=6 months; 2. PS Score >1; 3. Biopsy samples or pathology slice available; 4. More than one genetic mutation with mutant frequency>5% detected in Biopsy samples or pathology slice.

Exclusion criteria

Exclusion criteria: 1. with immune system disease; 2. with hematopathy.

Design outcomes

Primary

MeasureTime frame
Tumor size;Tumor markers;PS score;Progression-free survival;Overall survival;proportion of specific T lymphocytes in peripheral blood;?-interferon secretion by specific T lymphocytes in peripheral blood;—

Countries

China

Contacts

Public ContactXueming Du

Tianjin Beichen Hospital

dudaming73@163.com+86 13752713866

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026